[F:1][C:2]1[CH:3]=[C:4]([NH:9][C:10]([NH:12][C:13]2[N:14]=[C:15]([C:19]([O:21]CC)=[O:20])[N:16]([CH3:18])[CH:17]=2)=[O:11])[CH:5]=[CH:6][C:7]=1[CH3:8].[OH-].[Na+].Cl>C(O)C.O1CCCC1>[CH3:8][C:7]1[CH:6]=[CH:5][C:4]([NH:9][C:10]([NH:12][C:13]2[N:14]=[C:15]([C:19]([OH:21])=[O:20])[N:16]([CH3:18])[CH:17]=2)=[O:11])=[CH:3][C:2]=1[F:1]690 mg (2.15 mmol) of ethyl 4-({[(3-fluoro-4-methylphenyl)amino]carbonyl}amino)-1-methyl-1H-imidazole-2-carboxylate are suspended in 5 ml of ethanol and 12 ml of tetrahydrofuran. While cooling in ice, 2 ml (25 mmol) of 50% strength aqueous sodium hydroxide solution are added. The reaction mixture is stirred at room temperature overnight and then, while cooling in ice, acidified with 1N hydrochloric acid. The solution is extracted with dichloromethane. The organic phase is concentrated in vacuo.